A personalised new exercise app for people with long-term health conditions including heart and lung disease and diabetes is set to be piloted by researchers from the University of Leicester, working within the NIHR Leicester BRC.
Read More
Professor Melanie Davies, Director of the National Institute for Health and Care Research Leicester Biomedical Research Centre (BRC), played a central role in new study which has shown that the weight loss drug semaglutide may benefit a group of heart failure patients who have had few specific treatment options previously available to them.
Read More
We are delighted to invite you to the Leicester and Leicestershire Cancer Patient and Public Involvement and Engagement (PPIE) Group event on Thursday 26 October from 5pm-7pm.
We want to hear your views!
This is a really exciting opportunity to join our new Cancer Public Involvement group and to have your voice in shaping its work.
You will get the opportunity to meet some of the researchers from across the NIHR Leicester Biomedical Research Centre (BRC), the Leicester Experimental Cancer Medicine Centre (ECMC) and HOPE Cancer Trials Centre to find out about the research we’re undertaking into cancer, and how you can help to shape it.
Most importantly, we want to hear your views about what you’d like to see and get from this group.
Who we’re looking for:
We would like to hear from anyone living in the area who has a lived experience of (any) cancer, as well as healthy people who have any knowledge or interest in cancer and cancer research. You are welcome to bring a relative, friend or carer.
Event details
Date: Thursday 26 October 2023
Time: 5pm-7pm. Arrive any time from 5pm. Refreshments will be served. The event will begin at 5:30pm.
Address: University of Leicester, George Davies Centre, 15 Lancaster Road, Leicester LE1 7HA
Meeting room: George Davies Centre, Boardroom
To book your place, please email nihrleicesterppie@uhl-tr.nhs.uk by 6th October.
We hope to see you there.
A study looking at the longer-term impact of COVID-19 has found that nearly a third of patients displayed abnormalities in multiple organs five months after infection, some of which have been shown through previous work to be evidence of tissue damage.
Read More14 September 2023
Professor Fennell from the Personalised Cancer Prevention and Treatment theme of the NIHR Leicester BRC presented new preclinical data that show RSO-021, a first-in-class inhibitor of the antioxidant protein PRX3, reversed many of the features associated with aggressive mesothelioma tumor growth.
Read More
Some of the 11,000 people who’ve taken part in the ground-breaking Leicester research study, EXCEED, gathered at the University of Leicester’s Sir Bob Burgess building on 6 September to celebrate 10 years of the study.
Read More